Short Interest in Swedish Orphan Biovitrum AB (publ) (OTCMKTS:BIOVF) Increases By 35.9%

Swedish Orphan Biovitrum AB (publ) (OTCMKTS:BIOVF) was the recipient of a significant increase in short interest in the month of March. As of March 15th, there was short interest totalling 779,800 shares, an increase of 35.9% from the February 28th total of 573,800 shares. Based on an average trading volume of 100 shares, the short-interest ratio is presently 7,798.0 days. Currently, 0.2% of the shares of the company are sold short.

Swedish Orphan Biovitrum AB (publ) Stock Performance

BIOVF opened at $28.71 on Tuesday. The firm has a fifty day moving average price of $29.63 and a 200 day moving average price of $29.53. Swedish Orphan Biovitrum AB has a 1 year low of $22.87 and a 1 year high of $32.25. The stock has a market cap of $10.22 billion, a P/E ratio of 27.61 and a beta of 0.62. The company has a debt-to-equity ratio of 0.31, a current ratio of 0.91 and a quick ratio of 0.62.

Analysts Set New Price Targets

Separately, Barclays raised Swedish Orphan Biovitrum AB (publ) to a “strong-buy” rating in a report on Wednesday, January 8th.

About Swedish Orphan Biovitrum AB (publ)

Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. It offers Alprolix for haemophilia B; Aspaveli®/Empaveli for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet treatment of thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocytic lymphohistiocytosis(HLH); VONJO for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis; Zynlonta, an aggressive malignant disease; Kineret for cryopyrin associated periodic syndrome, rheumatoid arthritis, and still’s disease; Orfadin to treat hereditary tyrosinaemia type-1; and Synagis for serious lower respiratory tract infection.